New dendrimer as a contrast agent in magnetic resonance imaging (MRI)
A Spanish Research Institution has developed a new dendrimer that can be used as a contrast agent (CA) in magnetic resonance imaging (MRI). This new CA is non-toxic and it is expelled from live tissues in hours, making it the best option when periodical MRI tests are needed. Industrial partners are being sought to collaborate through patent license and research cooperation agreements.
Industrial partner in the bioimaging sector interested in the development and commercialization of the new contrast agent under a license agreement are sought. - Licensing agreement: the partner would license the technology to carry out the final development and commercialization of the contrast agent. - research cooperation agreement: the partner and the Spanish Institution could undertake a joint effort to further develop and optimize the product, addressing to specific needs of the market.
A Spanish Research Institution has developed a new contrast agent (CA) for magnetic resonance imaging (MRI). The inventors have expertise in developing new dendrimers for biological applications. MRI is a well-known imaging technique for non-invasive medical diagnosis and follow-up. CA provides images of different tissues, tumours and related pathological conditions of the same tissue in excellent detail due to their enhanced different brightness. The most widely used CAs are based on metal ions like gadolinium (Gd III). Gd can be considered as a toxic metal, it accumulates in some tissues (brain, bones, kidneys, etc.) and there is a relation between Gd administration and the development of nephrogenic systemic fibrosis. The new CA is a dendrimer with proxyl radicals. It is a Gd free non-toxic molecule with high solubility in biological fluids, long term contrast activity and it is expelled in hours from live tissues without accumulating in any of them. The characterístics of the new CA make it the ideal option when repeated MRI tests are needed. The Spanish Research Institution is searching for a company interested in the development and commercialization of this CA under a license agreement, and it is also open to establish a research cooperation agreement with the company, to further develop the product and optimise the production, according to the company interests.
Advantages and innovations
- Metal free non-toxic CA based on a dendrimer with proxyl radicals. - Non accumulation of CA in tissues, fastly expelled and easily degradated. - same contrast as Gd based CAs with 4 times less concentration. -Allows repeated imaging studies without health negative effects.
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below